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February 27, 2015 the LV outflow tract, which led to renewed LV growth in some fetuses. [4] [5] [6] In untreated children, as well as in nonresponders, a thick endocardial layer of cellular fibroelastic tissue, termed EFE forms, which restricts growth of the LV. Clinical observation indicates a direct observation between the LV growth of the fetus and the extent of EFE present at the time of the intervention on the valve. 4, 7 Thus, fetal intervention was combined with postnatal surgical removal of EFE tissue. 8 Technically successful EFE removal in both previously untreated children, as well as in the fetal nonresponders to valvotomy resulted in catch-up growth of left-sided structures of the heart, restoring biventricular physiology in a subset of cases, whereas in the children, where EFE could not be removed surgically, there was limited LV growth. 8, 9 These clinical findings underscore the likely fundamental role of EFE in HLHS. Therefore, preventive measures to inhibit formation of EFE tissue would be highly desirable. However, pathomechanisms underlying EFE formation are still scarce and specific therapeutic targets are not yet known. Here, we aimed to investigate the cellular origins of EFE tissue and to gain insights into the underlying molecular mechanisms.
EFE is a special type of fibrosis, which forms a de novo subendocardial tissue layer encapsulating the myocardium. It can be surgically removed without myocardial contamination, suggesting that it is derived from the endocardium and not from the myocardial stroma. 9 Furthermore, during embryonic heart development, the endocardial endothelium plays a significant role in the development of the valves and septa. Through a process termed endothelial to mesenchymal transition (EndMT), the endocardial endothelial cells form the (mesenchymal) endocardial cushion, which later gives rise to the valves and septum 10 Thus, we hypothesized that fibroblasts within the EFE layer originate from the endothelial cells of the endocardium via EndMT. Here, we demonstrate that the fibroblasts within the EFE layer indeed derive from endocardial endothelial cells via EndMT. Although several of the mutations that have been linked to HLHS directly affect EndMT, previous studies detected no genetic mutation in the vast majority of patients. We therefore explored whether the transcription level of affected genes could be regulated by the epigenetic mechanism of promoter hypermethylation. We demonstrate here that transcriptional suppression of bone morphogenetic proteins (BMP)7 through promoter methylation contributes to EndMT and thus EFE formation and that supplementation with exogenous recombinant BMP7 impedes EFE formation.
Methods
Ethics Statement
This research was approved by and conducted in accordance with the standards of the local institutional review committees of the Boston Children's Hospital and the Beth Israel Deaconess Medical Center. All studies with human tissue were performed with the approval of the institutional review board of Boston Children's Hospital.
All animals received humane care from the Animal Resources of Boston Children's Hospital or the Beth Israel Deaconess Medical Center, respectively, and all protocols were reviewed and approved by the Institutional Animal Care and Use Committee at Boston Children's Hospital or Beth Israel Deaconess Medical Center.
Subjects
EFE tissue from patients with HLHS were obtained as discarded material during open heart surgery between May 2009 and June 2010 at the Boston Children's Hospital and snap frozen for further analysis. Left ventricular control tissue was obtained from autopsy of infants who have passed away for reasons other than congenital heart disease.
Statistical Analysis
All qPCR data for RNA expression analysis (two or more biological replicates) were calculated using the ΔΔCT method. Student t test (GraphPad Prism 5.1) was used to obtain calculations of statistical significance. For multiple parameter comparison, 1-way Anova was used with Bonferroni adjustment for the VE-Cadherin luciferase experiment.
All further methods are described in detail in the Online Data Supplement.
Results Evidence for EndMT in EFE Tissue From HLHS Patients
In young infants with HLHS, the endocardial fibroelastic tissue forms a distinct subendocardial tissue layer with high collagen and elastin content, encapsulating the underlying myocardium ( Figure 1A and 1B). This EFE layer is removed from the underlying myocardium to allow the left ventricle to grow, as part of the operative therapy during biventricular repair, 11 enabling us to directly analyze fresh EFE tissue (for RNA, DNA, and microscopic analysis) without contamination from myocardial tissue. The main cell population in patients' EFE tissue is fibroblasts. To gain insights into the possible endocardial origin of EFE fibroblasts, we performed confocal analysis of the EndMT marker TWIST, as well as of double immunofluorescence for fibroblast markers FSP1 and αSMA, and the endothelial marker CD31, and expression analysis of the EndMT marker genes SNAIL, TWIST, and SLUG. 12 In 27 out of 30 patients, we detected both FSP1+/CD31+ and αSMA+/CD31+ double-positive cells and twist-positive cells. 54.4% of FSP1-positive fibroblasts and 30.3% of αSMA-positive fibroblasts also expressed CD31, suggesting that they are transitioning from endocardial cells into fibroblasts via EndMT (Figure 1C and 1D ; Online Figure I ). SNAIL, TWIST, and SLUG as well as mesenchymal markers αSMA and FSP1 were all significantly upregulated in EFE tissue as compared with healthy control samples, whereas endothelial markers CD31 and VE-Cadherin were downregulated ( Figure 1E ), suggesting that fibroblasts within EFE tissue possibly derive from the endocardium via undergoing EndMT.
BMP7 Promoter Is Hypermethylated in EFE Tissue
During normal embryonic heart development, the endocardial endothelial cells, which line the atrioventricular canal undergo an endothelial to mesenchymal transition to form the endocardial mesenchymal cushion which later gives rise to the septum and mitral and tricuspid valves, 10 prompting us to hypothesize that the EndMT observed in EFE formation is a reflection of the unique susceptibility of the embryonic endocardial endothelium to undergo EndMT. Because EndMT during embryonic heart development is regulated to a great extent by the TGFβ/BMP signaling pathways, [13] [14] [15] [16] [17] [18] we hypothesized that aberrant TGFβ/BMP signaling contributes to aberrant EndMT associated with EFE. We performed a qPCR array, which included 84 genes in the TGFβ/BMP signaling family, and we compared EFE tissue to normal neonatal left ventricular myocardium without heart disease ( Figure 2A ). Select regulated genes were then validated by real-time PCR ( Figure 2B ). Among the most regulated genes, we found BMP7, BMP5, and their signaling molecule SMAD5 downregulated ( Figure 2B ). In contrast, BMP2 and Noggin as well as collagen1A1 (the main constituent of cardiac matrix) were markedly upregulated in EFE tissue ( Figure 2B ). TGFβ1 was similarly significantly upregulated albeit less pronounced ( Figure 2B) . In addition, we tested relevant genes in the TGFβ/signaling pathway ID1-3 (as target genes for BMP signals) as well as TGFβ3 (which were not included in the PCR array) by real-time analysis. Both ID1 and ID2 were downregulated in EFE, whereas ID3 and TGFβ3 were not significantly regulated in EFE when compared with healthy control tissue ( Figure 2B ).
We next aimed to gain insights into the mechanisms underlying the persistent transcriptional suppression of select members of the BMP/TGF signaling family. Because BMP7, BMP5, and SMAD5 all contain CpG-rich motifs within their promoter regions, we hypothesized that observed persistent transcriptional suppression could be because of promoter hypermethylation. To explore whether decreased expression of BMP7, BMP5, and SMAD5 in EFE tissue is associated with promoter hypermethylation of these genes, a common epigenetic mechanism to reduce gene expression, we performed immunoprecipitation of methylated DNA, followed by PCRs for the BMP7, BMP5, and SMAD5 promoters (MeDIP assay; Figure 2C and Figure 2F ) for the BMP7 promoter, which both confirmed significantly increased both relative, as well as absolute BMP7 promoter CpG methylation in EFE when compared with healthy control tissue ( Figure 2E and 2F).
To test the biological impact of BMP7 promoter methylation, we cloned the BMP7 promoter into a CpG-free backbone and performed an in vitro methylation luciferase assay, demonstrating that hypermethylation of BMP7 promoter leads to reduced BMP7 expression ( Figure 2G ). This result suggests that the observed BMP7 promoter hypermethylation in EFE tissue likely causally contributes to the similar documented decrease of BMP7 expression.
BMP7 Blocks TGFβ-Induced EndMT Through Regulation of VE-Cadherin Promoter Activity
Because analysis of EFE tissues revealed that observed EndMT is associated with persistent suppression of BMP signaling and increased TGFβ signaling, we next aimed to gain further insights into the impact of BMP/TGFβ dysregulation on EndMT. Although BMP7 antagonizes TGFβ1-induced EndMT ( Figure 3A) , the molecular level of this mechanism has not yet been addressed. BMP7 and TGFβ1 each bind to distinct type II receptors, which then form complexes with specific Figure 2 . A, TGF-β/BMP qPCR array compared endocardial fibroelastosis (EFE) with healthy control heart tissues. The black arrow highlights the candidate genes which were altered in the EFE sample. B, Quantitative real-time polymerase chain reaction (PCR) analysis to validate the candidate genes selected from the TGF-β/BMP qPCR array. C and D, Methylated DNA immunoprecipitation (MeDIP) to assess BMP7 methylation in healthy and EFE hearts. C, Real-time PCR analysis quantitatively showed the methylation levels in control and EFE samples and (D) virtual gel images of BMP7 PCR products (upper panel) of immunoprecipitated 5mC DNA and the lower panel shows PCR products of input DNA as loading controls. E, BMP7 promoter methylation was determined by methylation-sensitive highresolution melting analysis. F, BMP7 promoter methylation status of the individual CpG sites in the EFE samples and in healthy hearts by bisulfite sequencing. Open and filled circles indicate unmethylated and methylated status, respectively. G, Luciferase assay assessed promoter activity of methylated human BMP7 promoter. Around 2.1 kb (from 2271 to 161 upstream of transcriptional starting site) human BMP7 promoter fragment was cloned into a CpG-free luciferase vector (upper panel). The luciferase activity from the methylated BMP7 promoter construct was significantly reduced as compared with unmethylated control construct. Data are shown as the mean±SD of 3 experiments. n.s., no significance; **P<0.01; ***P<0.001.
by guest on May 28, 2017 http://circres.ahajournals.org/ Downloaded from type I serine-threonine kinase receptors (activin receptor-like kinase (ALK) receptors). [19] [20] [21] [22] BMP7 binds specifically to ALK3 and ALK6 receptors, whereas TGFβ1 binds to ALK2 and ALK5 receptors. 19, 20, 22 Complex formation between BMP7 or TGFβ1 with type II and ALK type I receptors then leads to the intracellular signaling pathway mediated by SMAD proteins. SMAD1, SMAD5, and SMAD8 transduce BMP7 action, whereas SMAD2 and SMAD3 mediate TGFβ action in epithelial cells. SMAD4 is common to both pathways ( Figure 3B ).
We therefore transfected endothelial cells with a VE-cadherin luciferase construct and mimicked TGFβ1 and BMP7 signaling by additionally transfecting endothelial cells with constitutively active ALK3 (to mimic BMP7) and ALK5 (to mimic TGFβ1) receptors or with SMAD3, SMAD5, or SMAD4.
Mimicry of the BMP7 signaling pathway increased the activity of full-length VE-cadherin promoter in HCAEC. In contrast, transfection with CA-ALK5 and SMAD3 (TGFβ pathway) resulted in a >50% decrease in VE-cadherin promoter activity ( Figure 3B and 3C). Additional transfection in the same cells with CA-ALK3 and SMAD5 (BMP7 pathway) stimulated reinduction of VE-cadherin promoter activity by ≈2-fold, restoring it back to the basal level ( Figure 3C ).
Because Smad signaling pathways are not entirely specific for BMP7 and TGFβ, a similar cross talk by other members of the TGFβ-superfamily is possible. Nevertheless, these results provide evidence for a direct SMAD-dependent counteraction of the TGFβ pathway by BMP7 signaling, and vice versa, in cardiac endothelial cells.
To investigate potential therapeutic efficacy of exogenous recombinant human BMP7 (rhBMP7) in HLHS, we analyzed the presence of BMP7 type 1 (ALK3) and type 2 (BMPR2) receptors in human EFE tissue by immunofluorescence labeling. Both receptors were present abundantly in all human EFE tissues. An average of 91% of fibroblasts coexpressed ALK3 and 71% BMPRII. An average of 44% of CD31-positive endothelial cells also coexpressed ALK3 and 65% BMPRII (Online Figures III and IV) .
EFE in the Tie2Cre;Rosa-Stop-YFP Reporter Mouse Is Derived From EndMT
To clarify the origin of EFE tissue in the left ventricle, a rodent model was developed in which neonatal hearts were heterotopically transplanted in the abdomen of adult animals. 23 The rationale for this heterotopic transplantation was that human EFE develops in the fetus and in association with reduced blood flow, and this surgical technique allows to mimic this situation, by using immature donor hearts where intracavitary blood flow is reduced. Implantation of the heart was performed as a heterotopic infrarenal graft unloaded with aorta to the aorta and pulmonary artery to inferior vena cava anastomoses ( Figure 4A and 4B). These unloaded neonatal rodent hearts develop EFE tissue resembling human EFE tissue observed in patients with HLHS ( Figure 4A ). We have applied this technique, which was originally developed in rats to transgenic Tie2Cre;Rosa-Stop-YFP reporter mice (Figure 4C and 4D ). In these mice, cells of (Tie2-positive) endothelial origin express YFP, and they continue to express YFP, even if they change their phenotype. These neonatal donor reporter mouse hearts developed massive EFE 2-weeks after surgery, similar to the previously used neonatal rat hearts. Confocal analysis of the thickened endocardium revealed presence of YFP throughout the endocardium, revealing that cells within the EFE tissue are of endocardial origin ( Figure 4C and 4D) , whereas neonatal control reporter mouse hearts display only 1 thin (YFP-expressing) layer of endocardium ( Figure 4C ). Co-labeling of these hearts with the fibroblast markers FSP1 and αSMA showed that the FSP1-and αSMA-positive cells coexpressed YFP, indicating the endothelial origin of the fibroblasts ( Figure 4D ).
Because Tie2 is also expressed in hematopoietic cells, we aimed to address if immune cells infiltrate into the fibroelastic endocardium (and thereby account for the YFP-labeling not derived from Tie2-positive endocardial cells but from Tie2-positive hematopoietic progenitor cells). We therefore obtained ubiquitous EGFP rats, where all cells are labeled green ( Figure 4E , upper panel) and performed additional transplantation experiments, engrafting wild-type donor hearts into ubiquitously EGFP-positive recipient rats. No EGFP-positive cells are detected in the newly formed EFE tissue of the donor heart, indicating that immune cells from the recipient do not contribute to the EFE formation ( Figure 4E , lower panel).
Exogenous BMP7 Ameliorates Experimental EFE
We next sought to test the in vivo effect of rhBMP7 on inhibition of EFE. Because of the substantially bigger size of neonatal rat hearts when compared with neonatal mice, we chose to use the rat heart transplantation model for the BMP7 treatment study to decrease impact because of handling artifacts. Wild-type neonatal rat hearts were unloaded by heterotopic heart transplantation in wild type adult rats as previously described. Recipient rats were administered 30µg/kg rhBMP7 or vehicle buffer intraperitoneally every other day, starting on the day of surgery, with n=6 in each group. Transplanted hearts were harvested 2 weeks after surgery; sectioned from base to apex and analyzed for fibrosis with Masson's Trichrome stains (Figure 5A through 5D; Online Figure VII) . The fibrotic area was significantly reduced, and cardiomyocyte area was significantly increased in BMP7 administered rats when compared with vehicle-treated animals ( Figure 5A through 5D) . 
Discussion
Fibroelastosis of the endocardium is a congenital condition of unknown cause in which there occurs a diffuse thickening of the mural endocardium associated in most cases with myocardial hypertrophy, and leading to early death. This definition by Gowing from 1953 is still valid today. 11 Because various attempts have been made to unravel its cause, but until now a definite mechanism of EFE development could not be identified. Genetic predispositions have been proposed and infectious causes or hypoxia during fetal cardiac development. [24] [25] [26] [27] [28] [29] [30] Today, most forms of EFE are associated with congenital heart disease, most notably with hypoplastic left heart syndrome (HLHS), where clinical data suggest that EFE plays a role in the pathogenesis of the disease and is functionally most relevant. 4, 9, 31 Here, we provide evidence that EFE tissue derives from the endocardial endothelium involving aberrant EndMT associated with epigenetically induced BMP/TGFβ signaling dysregulation. We also provide evidence that such insight can be utilized to inhibit EndMT and EFE formation through supplementation of exogenous recombinant BMP7. Our finding that EFE tissue derives via aberrant EndMT from the endocardial endothelium is in agreement with several independent lines of research: EFE comprises a distinct tissue layer, which encapsulates the myocardium and which can be surgically removed without affecting the myocardial tissue, suggesting that it is of endocardial and not of myocardial stroma origin. Furthermore, clinical observations suggest that EFE development is directly associated with reduction of blood flow through the left ventricular cavity (in case of HLHS because of obstruction of the aortic valve), which further suggests that EFE formation is sensed and initiated in the endocardium and not within the myocardial compartment. 4, 9, 31 During embryonic heart development the endocardial endothelial cells of the atrioventricular canal undergo an endothelial-mesenchymal transition to form the mesenchymal endocardial cushion, which later develops into the septum and the valves of the heart suggesting that even in later stages the endocardial endothelial cells retain a unique propensity to undergo EndMT. 10, 32 In this regard, previous studies demonstrated that endocardial cells generate the endothelial cells of coronary arteries, 32 which may explain, why human coronary endothelial cells retain the capacity to undergo EndMT. 33 A recent study, which questioned contribution, of EndMT to cardiac fibrosis also reported the presence of fibroblasts of endocardial ancestry within myocardial fibrosis. 34 In this regard, our findings of EndMT involving endocardial endothelial cells provide additional evidence that heterogeneous embryonic ancestry of endothelial cells impacts their susceptibility to undergo EndMT and that the clinical context of EFE highlights the unique propensity of endocardial endothelial cells to undergo EndMT. The causal contribution of EndMT involving endocardial endothelial cells in the formation of EFE is also compatible with several lines of research which went alternate routes to identify underlying mechanisms: Several genetic mutations or copy number variations found in patients with HLHS, this far, although overall rare, are in genes which regulate EndMT via different pathways (eg,Notch1, Smad3, GJA1, NR2F2, and GATA4). [26] [27] [28] [29] [30] [35] [36] [37] [38] Hypoxia, another possible factor in the development of EFE, is also a strong inducer of EMT and EndMT in cell culture experiments. 39, 40 Various viruses have been suspected to cause primary EFE without other associated cardiac anomaly, and frequency of primary EFE has declined in association with eradication of the mumps virus through vaccination. 25 Several viruses have been shown to induce EMT, which makes viruses potential inducers of aberrant EndMT. [41] [42] [43] Of note, it has been described that in patients with primary EFE, adventitial perivascular hyperelastosis and fibrosis are often found in medium-sized and small arteries of parenchymatous organs other than the heart, suggesting a generalized activation of EndMT in these patients. 2 We further provide evidence that observed EndMT in EFE tissue is at least in part caused by imbalance of TGFβ/BMP signaling (TGFβ is increased and BMP signaling is impaired) and that EndMT and ultimately forming of EFE can be ameliorated through supplementation of exogenous recombinant BMP7. Through utilization of a ligand-free cell culture system, we demonstrate that TGF and BMP signaling directly counteract each other in the regulation of EndMT. Our studies further suggest that impaired BMP signaling in the context of HLHS-associated EFE is directly linked to transcriptional suppression of BMP5 and BMP7. During mouse development, BMP5 and BMP7 are coexpressed in the heart, and they can substitute for each other. The simultaneous lack of both BMP5 and BMP7 leads to embryonic lethality with endocardial cushion defects, whereas the individual BMP5 or BMP7 mutants have negligible developmental defects. 44 BMP2, which is not downregulated in EFE tissue, on the contrary, is necessary and sufficient to drive EndMT of endocardial cells to form the endocardial cushion. 45 In the vast majority of patients with hypoplastic left heart syndrome whole-exome sequencing to date failed to detect causal mutations. Our studies demonstrate that the observed imbalance of TGFβ /BMP in EFE tissue is at least in part because of aberrant promoter hypermethylation of BMP7. Thus, our approach to link HLHS to epigenetic silencing of select genes may provide an important new aspect of the molecular roots of this heterogeneous congenital heart disease. Mechanisms why specific genes are subject to aberrant hypermethylation in the context of EFE remain unclear, but to the best of our knowledge this issue has not been solved in any disease context yet.
Finally, we provide evidence that EndMT involving endocardial endothelial cells and formation of experimental EFE can be ameliorated through supplementation of exogenous recombinant BMP7. This is in line with previous studies from our group, which demonstrated that aberrant EndMT of vascular endothelial cells contributes to adult cardiac fibrosis and that by counteraction of TGFβ, BMP7 inhibits EndMT of adult cardiac endothelial cells and thereby ameliorates cardiac fibrosis in several mouse models of cardiac fibrosis, 33 suggesting that EndMT of coronary artery and of endocardial endothelial cells is controlled by common mechanisms. Because the 2 BMP7 receptors ALK3 and BMPRII are present in a significant portion of both endothelial cells and fibroblasts in EFE tissue, it is conceivable that rhBMP7 could be effective in ameliorating EFE in patients with HLHS. Because the different pathways of EndMT ultimately all lead to VE-cadherin suppression, and BMP7-induced SMAD5 activity is capable of reinducing VE-Cadherin expression (even outside the TGFβ pathway), we think that the ubiquitous rescue mechanism by BMP7 is most relevant, irrespective of the underlying EndMT mechanism, which may be not be same in all children with EFE. A schematic to illustrate the effect of BMP7 in different settings of known EndMT pathways is shown in Figure 6 . Of note, our data do not exclude the possibility that other BMPs are equally effective in inhibiting EndMT and EFE formation, but those to our knowledge have not yet been developed for systemic use, (while recombinant pro-BMP7 is in clinical use for compound fractures).
We are aware of a few limitations of our studies: because human endocardial endothelial cells to our knowledge have not yet been successfully cultured, we have used primary human coronary artery endothelial cells (HCAEC), which were isolated from the coronary arteries from a single donor, to induce EndMT in vitro. Coronary artery endothelial cells (unlike aortic) originate to a significant extent from endocardial cells, 32 and, at least to some degree retain similar biological potential as original endocardial cells, such as the capability to undergo EndMT on TGFβ treatment. Thus we think that HCAEC are well suited to substitute for the lack of primary endocardial cells with respect to understanding molecular mechanisms of both vascular and endocardial EndMT.
Furthermore, we induced EFE in neonatal Tie2Cre;RosaStop-YFP mouse hearts and demonstrate here that in this animal model cells of the EFE tissue are of endothelial origin. Because Tie2, in addition to endothelial cells, is also expressed in hematopoietic progenitor cells in the bone marrow, we also induced EFE in wildtype rats transplanted in recipient rats with ubiquitous EGFP expression. No EGFP-positive cells were found in the donor heart EFE tissue, ruling out the contribution of bone marrow cells to EFE formation.
No EFE develops if 2-week-old mouse hearts are used in this model of unloading, suggesting that immaturity is a necessary factor during EndMT in EFE formation. 23 We therefore think that most EndMT of endocardial cells happens during fetal EFE development. However, we still detect a fraction of cells undergoing active EndMT (by colabeling of CD31 and mesenchymal markers or of CD31 and EndMT transcription factors such as TWIST) in EFE tissue from children with HLHS, aged between a few days until preschool, suggesting that part of EFE tissue is maintained by active EndMT even at later developmental stages, while naturally, an absolute number of EndMT-derived fibroblasts cannot be provided by this technique.
Although we provide evidence that aberrant EndMT causes EFE, additional studies are needed to address how disturbed EndMT relates to abnormal valve formation and reduced ventricular growth in HLHS and in other congenital heart diseases associated with EFE. Because aberrant EndMT also contributes to cardiac fibrosis in adult forms of heart disease, studying EndMT in the context of fetal EFE may well contribute valuable knowledge to unravel fibrogenesis in chronic heart disease.
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What Is Known?
• Endocardial fibroelastosis (EFE) is a unique form of subendocardial fibrosis that complicates congenital heart disease.
• During embryonic heart development the endocardial endothelium undergoes an endothelial to mesenchymal transition (EndMT) to form the mesenchymal endocardial cushion.
What New Information Does This Article Contribute?
• Fibroblasts contributing to EFE originate from the endocardium via an aberrant EndMT.
• Hypermethylation of CpG island promoters of Bone Morphogenic
Proteins (BMP)-5 and -7 cause an imbalanced growth factor microenvironment and subsequently aberrant EndMT.
• In rodent models of EFE, administration of recombinant BMP-7 ameliorates EndMT and the formation of EFE tissue.
Endocardial fibroelastosis (EFE) is a unique form of subendocardial fibrosis that complicates congenital heart disease, including hypoplastic left heart syndrome (HLHS). While surgical removal of EFE tissue improves outcome of HLHS, preventive measures to inhibit EFE would be highly desirable. However, the mechanisms underlying EFE formation remains unclear and specific therapeutic targets have not been identified. During embryonic heart development the endocardial endothelium undergoes an endothelial to mesenchymal transition (EndMT) to form the (mesenchymal) endocardial cushion (which later gives rise to the valves and septum reference). Hence, we hypothesized that fibroblasts within the EFE layer originate from the endothelial cells of the endocardium via EndMT. Here, we demonstrate that the fibroblasts within the EFE layer derive from endocardial endothelial cells via EndMT. We also report that transcriptional suppression of BMP7 through promoter methylation contributes to EndMT and EFE formation and that supplementation with exogenous recombinant BMP7 impedes EFE formation. On the basis of these findings, it might be useful to assess the utility of the intrauterine administration of BMP7 in fetuses diagnosed with HLHS.
Methods in detail
Animals Model of Unloaded Heart Transplantation
Heterotopic heart transplantation was performed in C57/BL6 mice and Lewis rats as well as ubiquitous EGFP rats (strain F344-Tg(UBC-EGFP)F455Rrrc) from the Rat Resource &
Research Center (RRRC-P40OD011062) following a method previously described 1 . Young adult Lewis rats (100-120g) or C57/BL6 mice (20-25g) served as recipients and donor hearts were obtained from neonatal rats (2-4 days of age) or Tie2Cre;Rosa-Stop-YFP mice (7-10 days of age) respectively. Tie2Cre and Rosa-Stop-YFP mice have been described previously. Animals were anesthetized with ketamine (40-60mg/kg i.p.)/xylazine (10mg/kg i.p.) and isoflurane via endotracheal tube. The donor rats and mice received 300IU and 60IU heparin respectively, and the heart was explanted through a midline thoracic incision followed by storage in cold high potassium Krebs-Henseleit solution as previously described 1 . Implantation of the heart was performed as a heterotopic infra-renal graft unloaded with aorta to aorta and pulmonary artery (PA) to inferior vena cava (IVC)
anastomoses. Animals were survived for 2 weeks. The recipient rats received either 30 µg/kg rhBMP7 or vehicle buffer i.p. every other day, starting on the day of surgery.
DNA isolation
Tissues were first lysed in DNA lysis buffer (Qiagen, Hilden, Germany) then precipitated and isolated using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) followed by manufacturer's protocol.
Histological Analysis of Transplanted Hearts and EFE tissue
Snap frozen human EFE tissue embedded in OCT was sectioned and stained with
Hematoxylin & Eosin and Masson Trichrome staining. The same staining was applied to the paraffin-embedded rat and mouse hearts, which were sectioned, de-paraffinized and rehydrated with xylene and graded alcohol series prior to staining. Mouse hearts from Tie2Cre; Rosa-Stop-YFP mice and EGFP rats were additionally equilibrated into 30% sucrose prior to embedding to preserve endogenous YFP signal.
Fibrosis in rat hearts was quantified using the Image Pro Plus Software.
Immunofluorescence
Frozen human EFE tissue sections were fixed with ice cold acetone for 10min at -20°C, hours. Then the cells were starved with endothelial cell basal medium (Genlantis) overnight.
EndMT induction was performed by 1:10 dilution of HCAEC growth medium by endothelial basic medium (Genlantis, San Diego, USA) with 10 ng/ml TGFβ1 (R&D Systems, USA).
Medium with TGFß1 was changed every other day. BMP7 was added together with TGFß1 using 100 ng/ml for EndMT rescue.
Methylated DNA immunoprecipitation (MeDIP)
Methylated DNA was captured using Methylamp Methylated DNA capture Kit (Epigentek, Farmingdale, USA). 1.0µg of sonicated DNA was used in each antibody coated well and incubated at room temperature for 2 hours on a horizontal shaker. The captured DNA was released with proteinase K at 65 °C for 1 hour. DNA was eluted from the column and adjusted to a final volume of 100µl with nuclease-free water. For each sample, an input vial was performed using total sonicated DNA as loading control. To visualize the immunoprecipitated products, PCR products were loaded on the Bioanalyzer 2100 electrophoresis system (Agilent Technologies). Electrophoresis results are shown as a virtual gel as previously described 2 .
RNA extraction and quantitative real-time PCR
RNA was extracted from cells by direct lysis with Trizol regent (Ambion) and subsequent isolation using the PureLink RNA Mini Kit (Ambion) following the manufacturers protocol.
Tissues were homogenized using the TissueLyserLT (Qiagen) and RNA was extracted using the RNeasy Fibrous Tissue Mini Kit (Qiagen). cDNA was synthesized using the 
Bisulfite modification and Bisulfite genomic sequencing
200 ng of DNA from each sample were treated with sodium bisulfite using the "Cells-toCpG Bisulfite Conversion Kit" (Life technologies, UK) according to the manufacturer's protocol. Gene specific bisulfite sequencing analysis was performed as previously described 3 . In short, for sequencing of methylated BMP7 promoter region, the DNA samples were first bisulfite converted and amplified using primers, (forward:
AAAAGGATATAGGGATTGAGGGGTAAG, reverse:
CCGCCCTCCCCCCAACTATACCCAATAAATTC). Then the PCR product was gelextracted, purified and then ligated into pGEM-T Easy vector system (Promega). The sequencing experiment was performed by the Seqlab using T7 primer. The result was analyzed with BDPC, a webpage-based program 4 .
High resolution melting analysis (HRM)
Methylation sensitive high resolution melting experiments were performed as previously CCCAAAGACCTCCAAAACCT.
In vitro BMP7 promoter methylation and luciferase assay
For human BMP7 promoter methylation analyses, a 2.1 kb promoter fragment (2271 bp to BamHI and HindIII sites of pCpG-Basic vector 6 . The construct was in vitro methylated using M.SssI, CpG methyltransferase (NEB) according to manufacturer's protocol, and luciferase activity was measured by Duo-Glo luciferase assay system (Promega) as suggested by the company's instruction.
Regulation of VE-Cadherin promoter activity by Smad-dependent pathways.
In order to achieve optimal transfection efficiency, we immortalized HCAEC cells with vectors (Promega) as previously described [7] [8] [9] . The luciferase activity was determined by Duo-Glo luciferase assay system (Promega) and normalized luciferase activities to Renilla luciferase activity under the control of the CMV promoter.
